NeoPhore appoints Michael Shih as Chief Executive Officer
- Highly experienced corporate development leader with a track record of international pharma and biotech deal-making
- New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer
London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive Officer (CEO) and to the Board of Directors, effective immediately.
